This dosage information may not include all the information needed to use Valsartan safely and effectively. See additional information for Valsartan.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Congestive Heart Failure
Initial dose: 40 mg orally twice a day.
Maintenance dose: 80 to 160 mg twice daily. The dose should be increased to the highest dose tolerated by the patient.
Concomitant beta blockers and ACE inhibitors are not recommended.
Usual Adult Dose for Hypertension
Initial dose: 80 to 160 mg orally once a day.
Maintenance dose: 80 to 320 mg orally once a day.
Usual Adult Dose for Left Ventricular Dysfunction
Initial dose: 20 mg orally twice a day.
Maintenance dose: The initial dosage may be titrated upward within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dose of 160 mg twice daily as tolerated by the patient. If symptomatic hypotension or renal dysfunction occurs, consideration should be given to a dosage reduction.
Valsartan may be initiated as early as 12 hours after a myocardial infarction, and may be given with other standard postmyocardial infarction treatment, including thrombolytics, aspirin, beta blockers, and statins.
Usual Pediatric Dose for Hypertension
6 to 16 years:
Initial dose: 1.3 mg/kg once daily (up to 40 mg)
Maintenance dose: up to 2.7 mg/kg (up to 160 mg) once daily titrated according to patient response
If the calculated dosage does not correspond to the available tablet strengths, or if children are unable to swallow tablets, the use of a suspension (which can be prepared from the tablets) is recommended. The valsartan dose may need to be increased if the suspension is replaced by a tablet.
No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate less than 30 mL/min.
Renal Dose Adjustments
Caution should be used in patients with severe renal impairment (CrCl less than 10 mL/min); however, there is insufficient information to make a dosage recommendation.
Pediatric patients 6 to 16 years:
CrCl less than 30 mL/min: not recommended
Pediatric patients with hypertension where underlying renal abnormalities may be more common, renal function and serum potassium should be closely monitored as clinically indicated.
Liver Dose Adjustments
Mild to moderate liver disease: No dosage adjustment recommended
Severe liver disease: Data unavailable
Doses may be increased every 4 weeks up to 320 mg or a diuretic may be added. Adding a diuretic may be more effective than increasing the dose beyond 80 mg. Doses should be reduced in the presence of intravascular volume depletion.
Safety and effectiveness have not been established in pediatric patients less than 6 years of age.
Valsartan is not removed by hemodialysis.
No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate less than 30 mL/min/1.73 m2.
Compared with Caucasian patients, Black patients have a reduced blood pressure response to monotherapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers; however, the reduced response is largely eliminated if combination therapy that includes an adequate dose of a diuretic is instituted.